- December 25, 2017
- Posted by: Alton
- Category: Medical Cannabis News
Matching to New Frontier Data, the legal cannabis market was worthwhile around $6.6 billion in 2016, and it is projected to expand at a ingredient total annual development rate (CAGR) of 16% to attain over $24 billion by 2025. The medical market is projected showing strong progress at 12% CAGR through 2025, growing from $4.7 billion in 2016 to around $13.3 billion in 2025. Through the same period, sales of cannabis products for recreational use (adult-use) are projected to increase at a 21% CAGR, from $1.9 billion to $10.9 billion.
The projections derive from data from state governments where cannabis has been legalized by January 2017, and don’t include any potential legalization initiatives throughout the forecast period. Pivot Pharmaceuticals Inc. (OTC: PVOTF), Emblem Corp. (OTC: EMMBF), Namaste Technology Inc. (OTC: NXTTF), Cannabis Wheaton Income Corp. (OTC: CBWTF), Emerald Health Therapeutics Inc. (OTC: EMHTF)
Major market segments for the cannabis industry, including the status of California, are anticipated to become types of how to control the new and growing cannabis industry. Giadha Aguirre de Carcer, New Frontier Data CEO, discussed, “Significant changes already are underway in California for medical cannabis and mature use laws and regulations, which we see will have major implications for the cannabis industry, including ecommerce and delivery services in their state… As the most significant state in the united states – and the most significant potential market for cannabis products – the implications for the expansion of the industry because of California’s adult use market can’t be overstated.”
Pivot Pharmaceuticals Inc. (OTCQB: PVOTF) also just detailed this week on the Canadian STOCK MARKET under the Ticker ‘PVOT’. Last night the company released breaking media that, “the business has authorized a Binding Notice of Intent to obtain ERS Holdings, LLC (“ERS”), a privately-held California company. ERS is rolling out a branded technology called “RTIC” – PREPARED TO Infuse Cannabis (“the Patent”), and in addition has registered several continuation patents associated with the change of cannabis engine oil into natural powder for infusion into a number of food and drink products such as pills, K-Cups, stick packages, cooked mixes, liquid images, necessary protein shakes, topicals, creams, and bottled drinks.
In trade for 100% of ERS Holdings, LLC (Patent Stock portfolio and Trademarks for “Instant THC(TM)” and “Instant CBD(TM)”) Pivot can pay ERS Holdings USD $1,000,000 and 5,000,000 Common Stocks (“The Shares”) of Pivot Pharmaceuticals Inc. The Stocks will be at the mercy of a six (6) month limitation with the first 25% of the full total number of Stocks to be released six (6) calendar months following the shutting night out, with 25% to be released every one fourth thereafter, according to the escrow contract to be carried out at exactly the same time as the Definitive Arrangement. Conclusion of the acquisition is at the mercy of regulatory endorsement and standard shutting conditions.
Current cannabis product formulations are either badly assimilated topicals and orals or inhaled and smoked carcinogens. Health mindful individuals who seek the restorative benefits associated with cannabis minus the negative health results represent a sizable untapped demographic. This demographic is also inundated with edible product alternatives that are saturated in sweets, such as chocolate or confectionary. Health seeking consumers who use cannabis daily signify a sizable market chance of Pivot. The acquisition of ERS allows Pivot to increase its growing pipeline of cannabis structured products.
Developed by Ross Franklin and Ed Rosenthal, the technology “relates generally to methods and compositions of subject for enabling focused cannabis essential oil to be steady, emulsifiable and flavorless for use in hot drinks or food by merging cannabis engine oil with a starch natural powder or starch-derived natural powder. Embodiments also relate with a number of culinary uses for the stabilized, emulsified, flavorless focused cannabis oil natural powder.”
Mr. Franklin, ERS’ CEO, said that “after being courted by a few of Canada’s major cannabis companies, we chosen the Pivot team to help generate income from our patent. Their management team has intensive pharmaceutical and nutraceutical industry experience and an extraordinary history of bringing products to advertise. As well as the food and drink market segments, we also anticipate integrating “RTIC” into Pivot’s current topical ointment, dental and nanoparticulate pipeline.”
Dr. Patrick Frankham, CEO of Pivot Pharmaceuticals explained that “Pivot thinks that the expected changes in cannabis legislation in Canada and California provides an possibility to release multiple products in to the medical and recreational marketplaces in 2018. Our company is delighted that Ross Franklin and Pat Rolfes from ERS have chosen Pivot to help change their patents and techniques into restorative consumer goods. Pivot is within ongoing conversations with several Canadian Licensed Companies and Licensed Retailers to be able to speed up commercialization of our own large pipeline of technology powered products. If the right joint venture spouse is not discovered by January 2018 Pivot will seek an authorized Seller designation from Health Canada and initiate construction of its production facility. Because of this, Pivot has employed CBRE, the world’s major commercial real property organization, to help assist in the website selection process.”
Emblem Corp. (OTC: EMMBF) is a completely integrated certified designer and distributor of medical cannabis and cannabis derivatives in Canada under the ACMPR (Usage of Cannabis for Medical Purposes Polices). On Dec 18th, the business announced the kick off of four cannabis natural oils that is now able to be bought online or by cellphone from its award-winning customer support team. “We have been particularly thrilled by our CBD natural oils,” says Nick Dean, CEO of Emblem Corp. “CBD is not psychoactive, and a recently available report from the planet Health Organization implies CBD to be a powerful treatment for epileptic seizures, between lots of other medical ailments. Physicians are progressively embracing CBD-rich strains because of their patients.”
Namaste Technology Inc. (OTCQB: NXTTF) can be an emerging innovator in vaporizer and accessories space. Just lately, the company released a Notice of Intention with Supreme Pharmaceuticals Inc. The LOI, agreed upon by Supreme’s wholly owned or operated subsidiary, 7ACRES, and Namaste’s wholly possessed subsidiary, Cannmart Inc. (“CannMart”), provides that Supreme will give CannMart with reduced selection of high quality dried out cannabis flower which is offered in the business’s medical market place. Supreme is targeted on producing high quality cannabis through a committed action to carefully curated genetics, quality targeted cultivation procedures and a post-harvest process which includes a 14-day complete plant drying out process and hands finishing of every flower. Beneath the conditions of the LOI, Namaste has focused on use Supreme as a preferred merchant as related to possible top quality partnerships, in addition to provide for Namaste’s in-house top quality medical cannabis. All Supreme cannabis will keep the 7ACRES producer’s tag. Namaste thinks that Supreme’s Business to Business (B2B) circulation model works with well with Namaste’s give attention to becoming Canada’s leading online dealer for medical cannabis.
Cannabis Wheaton Income Corp. (OTCQB: CBWTF) is the first cannabis loading company on the planet. On November 1, 2017, the business announced the final of the acquisition out of all the issued and excellent stocks of RockGarden Medicinals (2014) Inc. pursuant to the conditions of any definitive talk about purchase contract dated Oct 31, 2017. The Acquisition furthers the business’s streaming program strategy by giving the business additional resources and regulatory tools to help speed up Wheaton Licensing Program members’ pathway to licensing under the Usage of Cannabis for Medical Purposes Laws (the “ACMPR”). Situated in Carleton Place, Ontario, RockGarden is a privately possessed certified developer of cannabis pursuant to the ACMPR. On August 25, 2017 RockGarden was awarded a cultivation permit.
Emerald Health Therapeutics Inc. (OTCQX: EMHTF) subsidiary Emerald Health Botanicals Inc. is a qualified Designer under Canada’s Usage of Cannabis for Medical Purposes Restrictions (“ACMPR”) and is also authorized to create and sell dried out medical cannabis bloom and medical cannabis engine oil. On November 29th, the business released that its qualified producer application, published through Emerald Health Botanicals because of its new Richmond, BC greenhouse center under Canada’sACMPR has fulfilled certain requirements of the paper-based overview of Health Canada’s Office of Medical Cannabis (“OMC”). The OMC proved reasonable provision of information about the security plan, record keeping and monitoring systems, QA records, and security clearance for key employees, among other items. Emerald aspires to harvest out of this new 75,000 rectangular ft of cultivation space by 3Q 2018 and strategies to possess over 500,000 rectangular legs of cultivation space built here by 12 months end. “With significant, secure resource from our large-scale Pure Sunfarms collaboration and Emerald facilities, and our value-added product development programs, we plan to be well-positioned for development in the adult use market in the next to and long run,” said Dr. Avtar Dhillon, Exec Chairman of Emerald.
Source:- PR News Wire